Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
Tóm tắt
Ibrutinib was introduced in Japan in 2016 as a new oral treatment option for patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). There is increasing interest from the Japanese government to assess economic aspects of new medical interventions, especially in the area of oncology. We describe the treatment patterns of Japanese patients with CLL, estimate the cost of the disease from a health insurance perspective, and predict the budget impact of the introduction of ibrutinib. A budget impact model was set up and populated with data that were collected from a survey of Japanese hematologists (n = 202) and official statistics. Uncertainty was addressed by one-way sensitivity analysis of several model parameters. Among the 2000 Japanese CLL patients, 42.2% have not yet commenced medical treatment, 29.1% were on a treatment break, and 26.8% received medical treatment, mainly rituximab in combination with either fludarabine or bendamustine. Among the patients under medical treatment, 65.7% were receiving first-line treatment and 34.3% were receiving second-line or later treatment. In Japan, the estimated burden of illness for 2015 was ¥1563 million for RR CLL and ¥5471 million for overall CLL. The expected average budget impact of introducing ibrutinib is ¥3077 million per year for the next 5 years. Due to low disease prevalence, the burden of illness in Japan is low compared with Western countries.
Tài liệu tham khảo
Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67:152–7.
Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int. 2008;58:174–82.
Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, et al. Chronic lymphocytic leukemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809–19.
Wu SJ, Huang SY, Lin CT, Lin YJ, Chang CJ, Tien HF, et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986–2005: a distinct increasing trend with birth-cohort effect. Blood. 2010;116:4430–5.
Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–45.
Ruchlemer R, Polliack A. Geography, ethnicity and “roots” in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(6):1142–50.
Lim RB, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST, et al. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674–87.
Isobe Y, Tomomatsu J, Tsukune Y, Tsukada N, Sasaki M, Sugimoto K, et al. Diagnostic problems among chronic lymphocytic leukemia and other indolent B-cell leukemias in a Japanese population. Intern Med. 2012;51(15):1977–81.
Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–9.
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.
Ministry of Finance. Interest rate. Tokyo: 2015. http://www.mof.go.jp/english/jgbs/reference/interest_rate/index.htm. Accessed 1 Dec 2015.
Ministry of Health, Labor and Welfare. Patient survey (KanjaChosa). Tokyo: 2009. http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/index.html. Accessed 1 Nov 2015.
Statistics Japan. Current population estimates. Tokyo: 2013. http://www.stat.go.jp/english/data/jinsui/2013np/index.htm. Accessed 1 Nov 2015.
Santos FP, O’Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J. 2012;18(5):396–403.
Ministry of Health, Labor and Welfare. Master of medical intervention (Iryo shinryou koui master). Tokyo: 2016. http://www.iryohoken.go.jp/shinryohoshu/downloadMenu/. Accessed 25 May 2016.
Ministry of Health, Labor and Welfare. Master of pharmaceutical products (Iyakuhin master). Tokyo: 2016. http://www.iryohoken.go.jp/shinryohoshu/downloadMenu/. Accessed 25 May 2016.
Japanese Society of Hematology. Treatment guideline for hematopoietic tumor, therapy evaluation. http://www.jshem.or.jp/gui-hemali/1_5.html.
Chang JE, Kahl BS. Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 2012;13(10):1495–505.
Leblond V. Use of bendamustine in chronic lymphocytic leukemia patients with co-morbidities. Eur Oncol Haematol. 2012;8(1):52–7.
Kotiah S. Chronic lymphocytic leukemia treatment protocols. New York: Medscape. http://emedicine.medscape.com/article/2005390-overview. Accessed 23 May 2016.
Wang K, Li P, Chen L, Kato K, Kobayashi M, Yamauchi K, et al. Impact of the Japanese diagnosis procedure combination-based payment system in Japan. J Med Syst. 2010;34(1):95–100.
Ministry of Health, Labor and Welfare. Point table of DPC. Tokyo. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000039920.html. Accessed 25 May 2016.
Japan Blood Products Association. Kensensho (infections). Tokyo. http://www.ketsukyo.or.jp/disease/infection/infection_02.html. Accessed 24 May 2016.
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–66.
Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–65.
Blankart CR, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T, et al. Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis. 2013;8:32.
Statistics Japan. Labour force survey. Tokyo: 2016. http://www.stat.go.jp/english/data/roudou/lngindex.htm. Accessed 15 Nov 2016.
Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R, et al. Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care. 2006;15:379–85.
Tiessen J, Kambara H, Sakai T, Kato K, Yamauchi K, McMillan C, et al. What causes international variations in length of stay: a comparative analysis for two inpatient conditions in Japanese and Canadian hospitals. Health Serv Manag Res. 2013;26(2–3):86–94.
Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252–8.
Jang MA, Yoo EH, Kim K, Kim WS, Jung CW, Kim SH, et al. Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. Int J Hematol. 2013;97(3):403–8.
Wu SJ, Chiang CJ, Lin CT, Tien HF, Lai MS. Improving but inferior survival in patients with chronic lymphocytic leukemia in Taiwan: a population-based study, 1990–2004. PLoS ONE. 2013;8(4):e62930.
Laugesen M, Glied S. Higher fees paid to US physicians drive higher spending for physician services compared to other countries. Health Aff. 2011;30(9):1647–56.
Danzon PM, Chao L-W. Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19(2):159–95.
Mahon F, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of Imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.